LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 3 | H23 | 72 | hr | 1401 | 4073 | 4272 | 0.9533 | 0.9414 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 1 | H22 | 72 | hr | 1401 | 4194 | 4139 | 1.0133 | 1.0170 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 2 | H22 | 72 | hr | 1401 | 3850 | 4095 | 0.9401 | 0.9217 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 3 | H22 | 72 | hr | 1401 | 4096 | 4272 | 0.9587 | 0.9483 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 1 | H21 | 72 | hr | 1401 | 4116 | 4139 | 0.9944 | 0.9929 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 2 | H21 | 72 | hr | 1401 | 4047 | 4095 | 0.9882 | 0.9847 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 3 | H21 | 72 | hr | 1401 | 4177 | 4272 | 0.9777 | 0.9721 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 1 | H20 | 72 | hr | 1401 | 4212 | 4139 | 1.0176 | 1.0225 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 2 | H20 | 72 | hr | 1401 | 4184 | 4095 | 1.0216 | 1.0279 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 3 | H20 | 72 | hr | 1401 | 4361 | 4272 | 1.0207 | 1.0257 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 1 | H19 | 72 | hr | 1401 | 4240 | 4139 | 1.0244 | 1.0311 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 2 | H19 | 72 | hr | 1401 | 4401 | 4095 | 1.0746 | 1.0953 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 3 | H19 | 72 | hr | 1401 | 4258 | 4272 | 0.9966 | 0.9958 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 1 | O24 | 72 | hr | 1401 | 3582 | 3978 | 0.9003 | 0.8652 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 2 | O24 | 72 | hr | 1401 | 3875 | 4213 | 0.9197 | 0.8973 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 3 | O24 | 72 | hr | 1401 | 4036 | 4545 | 0.8878 | 0.8646 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 1 | O23 | 72 | hr | 1401 | 3418 | 3978 | 0.8591 | 0.8081 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 2 | O23 | 72 | hr | 1401 | 3944 | 4213 | 0.9361 | 0.9185 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 3 | O23 | 72 | hr | 1401 | 4254 | 4545 | 0.9358 | 0.9233 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 1 | O22 | 72 | hr | 1401 | 3431 | 3978 | 0.8624 | 0.8126 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 2 | O22 | 72 | hr | 1401 | 3749 | 4213 | 0.8898 | 0.8582 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 3 | O22 | 72 | hr | 1401 | 3941 | 4545 | 0.8669 | 0.8386 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 1401 | 3143 | 3978 | 0.7900 | 0.7101 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 1401 | 3598 | 4213 | 0.8540 | 0.8107 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 1401 | 3896 | 4545 | 0.8570 | 0.8263 |